A Feasibility Study of Hypoxia Imaging in Patients With Prostate Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)
Inclusion Criteria:
- Age => 18 years
- Histologic diagnosis of adenocarcinoma of the prostate
- Bulky intermediate risk, high risk or metastatic prostate cancer
Bulky intermediate risk: cT1-2 with >50% of diagnostic biopsy cores containing cancer and
Gleason 6 or 7 and prostate specific antigen (PSA) >10 and ≤20 OR
High risk:
cT1-2 with Gleason score ≥8; or cT1-2 with PSA >20; or cT3 OR N+ and/or M1 disease OR
Newly diagnosed hormone-refractory prostate cancer - Intention to treat using
radiotherapy +/- concurrent and adjuvant hormonal therapy
- Intention to treat with radiotherapy, hormonal therapy, other systemic treatment for
prostate cancer, or a combination of these according to the Princess Margaret
Genitourinary Site policies.
- Previous or concurrent anti-cancer therapy for the PET FAZA target lesion allowed
- Ability to provide written informed consent to participate in the study
Exclusion Criteria:
- Inability to lie supine for more than 60 minutes
- Patients taking the drug disulfiram (Antabuse)
- Contraindications for MRI: only applicable in cases where the PET FAZA target lesion
is identified as the prostate gland. Patients with target lesions at other anatomic
sites will not undergo MR imaging.
- Patients weighing > 136 kg